Radiosurgery, Stereotactic Approach (SRS/SBRT)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage policy for stereotactic radiosurgery (intracranial SRS) and stereotactic body radiotherapy (SBRT) describing indications, coverage criteria, and investigational exclusions for Blue Cross Blue Shield of North Carolina.
Minor editing to the When Covered and Policy Guidelines sections for clarity; no change to policy statement.
Deleted HCPCS codes G6003–G6014 effective 1/1/2026 in a code update.
Codes 77402, 77407 and 77412 removed from the Billing/Coding section.
Coverage Criteria for SRS and SBRT
Covered SRS Indications (intracranial)
BCBSNC will provide coverage when medically necessary and the following intracranial indications apply:
Covered SBRT Indications (extracranial)
SBRT may be considered medically necessary for the following extracranial indications when all listed conditions for each indication are met:
Oligometastases Coverage Criteria
Oligometastatic disease is covered when ALL of the following are met:
SRS — Brain metastases
SRS for brain metastases is covered when performance status and systemic disease criteria are met:
SBRT — Extracranial indications
SBRT may be considered medically reasonable for the extracranial disease sites and conditions listed below (site-specific criteria apply where noted):
References: policy guidelines on SBRT utility and pancreatic caution.
Covered indications (historical additions)
Historical When Covered updates and clarifications (documented additions to covered indications over time):
Stereotactic radiosurgery (SRS) is investigational for any applications other than the intracranial and extracranial indications explicitly listed as covered in this policy. This includes SRS for functional disorders other than trigeminal neuralgia (for example, chronic pain or tremor). Procedures considered investigational may be denied.
Stereotactic body radiation therapy (SBRT) for oligometastatic disease is not medically necessary when the policy’s oligometastases criteria are not met. The policy requires that covered oligometastases meet all specified characteristics (see section B. #8): six or fewer radiographically apparent lesions, no lesion > 6 cm, Karnofsky Performance Status ≥70, and life expectancy ≥6 months. Failure to document these criteria may result in denial.
The role of SBRT for pancreatic cancer remains unresolved. The policy notes that combined chemo‑radiotherapy is a key component for locally advanced pancreatic cancer and that the benefit of SBRT for pancreatic tumors is not established. Studies show promising local control but no clear survival advantage and some reports of unacceptable toxicity, so SBRT for pancreatic adenocarcinoma should be considered cautiously and only where consistent with the policy’s covered indication (definitive treatment for inoperable disease without distant metastases).
A historical correction was recorded on 2/25/20 clarifying the When Not Covered statement: "Stereotactic body radiation therapy (SBRT) for oligometastases is considered not medically necessary when criteria listed above in section B #8 are not met." This correction amended a numerical reference but did not change policy intent.
Rephrased for clarity: SBRT for oligometastatic disease is considered not medically necessary when the defined oligometastases coverage requirements are not satisfied — specifically, when there are more than six radiographically apparent lesions, any lesion exceeds 6 cm, the patient’s KPS is <70, or expected survival is <6 months.
Stereotactic radiosurgery for functional disorders other than trigeminal neuralgia (for example, cluster headache, chronic pain, or tremor) is listed as investigational and therefore not covered. Earlier policy revisions added and expanded this exclusion; the policy history documents that functional indications other than trigeminal neuralgia have been considered investigational in prior reviews.
A recorded editorial correction dated 2/25/20 fixed a typographical error in the When Not Covered section related to oligometastases wording. The corrected text confirms that SBRT for oligometastases is not medically necessary when criteria in section B #8 are not met; no change to clinical intent was made.
Billing and Coding
| 77301 | Physics consultation and/or treatment planning for SRS/SBRT (added previously) |
| 77338 | Delivery of radiation treatment SRS-related code (added previously) |
| 77295 | Prostate or other special planning code (added previously) |
| 77431 | Special care/plan code added 3/22/22 |
| 77470 | Special radiation therapy code added 3/22/22 |
| G6003 | HCPCS code deleted effective 1/1/2026 |
| G6004 | HCPCS code deleted effective 1/1/2026 |
| G6005 | HCPCS code deleted effective 1/1/2026 |
| G6006 | HCPCS code deleted effective 1/1/2026 |
| G6007 | HCPCS code deleted effective 1/1/2026 |
Provider Actions and Documentation Requirements
Prior review may be required per benefit booklet
Prior review (prior authorization) may be required per the individual member's benefit booklet.
Check member certificate for prior review requirements
Refer to the individual member’s benefit booklet for prior review/precertification requirements; prior review may be required per the member certificate.
Verify benefits, eligibility, and obtain required authorizations
Verify benefits and eligibility before applying these medical and payment guidelines; this policy is informational and is not an authorization — obtain any required authorizations per the member's contract.
Surgical resection preferred when feasible (context for sequencing)
Surgical resection is referenced as the preferred option for certain primary tumors when feasible; SBRT is considered when the patient is not a candidate for surgery or has refused surgery after informed consent.
- Example: Stage IA-IIA NSCLC — SBRT indicated when lesion ≤5 cm and patient is not a candidate for surgical resection or has refused surgery after informed consent (see coverage criteria).
- Example: Hepatocellular carcinoma and primary renal cell carcinoma — SBRT when disease is non-metastatic and patient is not a surgical candidate or refuses surgery.
Follow Billing/Coding guidance and confirm benefit applicability
Follow billing and coding guidance in the policy's Billing/Coding section; inclusion of a code does not guarantee reimbursement and applicability depends on the member’s benefits.
Be prepared to provide medical records when requested
BCBSNC may request medical records for determination of medical necessity; provide the documentation requested to support coverage decisions.
Confirm benefit applicability and prior review in member booklet
Refer to the member's benefit booklet for benefit applicability and prior review/prior authorization requirements; member benefits vary by plan and should be reviewed before applying this policy.
Include all specific clinical details when records are requested
When medical records are requested, include all specific information needed to make a medical necessity determination; letters or explanations alone are insufficient unless they contain all required details.
- Provide imaging reports, lesion counts and sizes, Karnofsky Performance Status, life expectancy estimates, prior treatments, and documentation of surgical candidacy or refusal where relevant.
Submit complete medical records when requested
When BCBSNC requests medical records for medical necessity determination, submit complete records — letters of support alone are not sufficient unless they include all specific information needed.
Investigational indications may be denied
SRS/SBRT provided for indications considered investigational by the policy (i.e., indications not listed as covered) may be denied.
- Examples include functional disorders other than trigeminal neuralgia and any extracranial SBRT indications not listed as covered.
Risk of denial if oligometastases criteria are not met
SBRT for oligometastases that does not meet the policy’s oligometastases criteria (e.g., more than six lesions, any lesion >6 cm, KPS <70, or life expectancy <6 months) may be denied as not medically necessary.
- Oligometastases coverage requires: ≤6 radiographically apparent lesions; none >6 cm; KPS ≥70; life expectancy ≥6 months.
Absence of requested information may lead to denial
BCBSNC may request medical records for determination of medical necessity; failure to provide the specific information requested may lead to denial.
Incomplete documentation may result in denial
BCBSNC may request medical records for determination of medical necessity; lack of the requested documentation (or incomplete documentation) may result in denial of coverage.
Background
SRS and SBRT are precise, high‑dose, conformal radiation techniques that deliver targeted radiation to anatomic lesions while minimizing dose to adjacent normal tissues. SRS generally refers to highly focused, typically single‑fraction treatment directed at intracranial lesions, whereas SBRT refers to stereotactic treatments for extracranial sites that are often delivered in a small number of fractions. Platforms include cobalt‑60 gamma devices, LINAC‑based systems (including robotic delivery), and particle beams; image guidance and immobilization are used to achieve conformality and spare adjacent structures.
Definitions
Revision History
Entire policy extensively revised; added multiple covered indications (craniopharyngiomas, glomus jugulare tumors, radioresistant spinal/vertebral metastases), added prostate and hepatocellular indications, oligometastases indications, KPS scale, and added CPT codes 77301, 77338, 77295; Specialty Matched Consultant Advisory Panel review 5/15/2013; Medical Director review 5/2013.
Reference list updated with no change to policy statement.
Specialty Matched Consultant Advisory Panel review meeting 6/24/2014; no change to policy statement.
Extensive updates to Description section and added tremor as investigational indication under When Not Covered; reference added.
Billing/Coding edits: added HCPCS codes G6003–G6014 and deleted G0173 and G0251; multiple CPT codes deleted effective 1/1/2015.
Specialty Matched Consultant Advisory Panel review 5/27/2015; no change to policy statement.
Updated Description section and added reference; no change to policy intent.
Specialty Matched Consultant Advisory Panel review 5/25/2016; no change to policy statement.
Specialty Matched Consultant Advisory Panel review 5/31/2017; no change to policy statement.
Reference added.
Specialty Matched Consultant Advisory Panel review 5/2018 and Medical Director review 5/2018; no changes to policy statements.
Added uveal melanoma and mesial temporal lobe epilepsy to When Covered; added primary renal cell carcinoma to extracranial indications; removed treatment of seizures and uveal melanoma from When Not Covered; Medical Director review 4/2019.
Specialty Matched Consultant Advisory Panel review 5/15/2019; no changes to policy statements.
Added pancreatic adenocarcinoma as definitive treatment for inoperable disease without distant metastases to When Covered; Medical Director review 9/2019.
Corrected typo in When Not Covered clarifying oligometastases numerical reference; no change to policy intent.
Specialty Matched Consultant Advisory Panel review 5/20/2020; reference added; no change to policy statement.
Specialty Matched Consultant Advisory Panel review 5/19/2021; references added and Policy Guidelines updated; no change to policy statement.
Added Radiology Maximum Units guidelines for SBRT treatment course and added CPT codes 77431 and 77470 to Billing/Coding; Notification given 3/22/22 for effective date 6/1/22; Medical Director review 3/2022.
Specialty Matched Consultant Advisory Panel review 5/18/22; no change to policy statement.
Removed bullet (d) under Section B #2 (anticoagulation statement) from When Covered; Specialty Matched Consultant Advisory Panel review 5/17/2023.
Per Medical Director/CAP review clarified SRS as single-fraction treatment and added medical necessity coverage for high-risk in B.2.a; fractionation statement clarified for readability.
Added coverage criteria for postoperative meningiomas (grades II–III) to When Covered section A. #5; Specialty Matched Consultant Advisory Panel review 5/21/2025.
Deleted HCPCS codes G6003–G6014 effective 1/1/2026 as part of a code update.
Removed CPT codes 77402, 77407, and 77412 from the Billing/Coding section.
Minor editing to the When Covered and Policy Guidelines sections for clarity; Specialty Matched Consultant Advisory Panel review 5/2026 and Medical Director review 5/2026; no change to policy statement.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.